For example, these drugs have been evaluated in clinical trials with patients with diabetic kidney disease [206], with a reduction in p16INK4A- and p21CIP-1-expressing adipocytes and circulating SASP factors. This evidence concerns the gene CDKN2A and diabetic kidney disease.